Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.
Baird JH, Epstein DJ, Tamaresis JS, Ehlinger Z, Spiegel JY, Craig J, Claire GK, Frank MJ, Muffly L, Shiraz P, Meyer E, Arai S, Brown JW, Johnston L, Lowsky R, Negrin RS, Rezvani AR, Weng WK, Latchford T, Sahaf B, Mackall CL, Miklos DB, Sidana S.
Baird JH, et al.
Blood Adv. 2021 Jan 12;5(1):143-155. doi: 10.1182/bloodadvances.2020002732.
Blood Adv. 2021.
PMID: 33570626
Free PMC article.
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has significantly improved outcomes in the treatment of refractory or relapsed large B-cell lymphoma (LBCL). We evaluated the long-term course of hematologic recovery, immune reconstitution, and infectious compl …
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has significantly improved outcomes in the treatment of refractory or relapsed …